Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Inner Mongolia Yongye Biotechnology is a leading Chinese agricultural biotechnology company that specializes in the research, development, and manufacturing of humic acid-based products. The company's flagship product, Shengmingsu, is a liquid nutrient used to enhance crop yields and improve the quality of various agricultural products by facilitating nutrient absorption. In addition to plant nutrients, the company produces animal feed supplements aimed at improving the health and growth rates of livestock. Formerly listed on the NASDAQ as Yongye International, the company was taken private in 2014 by a consortium led by its founder and Morgan Stanley Private Equity Asia. It operates primarily within the Chinese market, leveraging its proprietary fulvic acid technology to address agricultural productivity challenges. The company is headquartered in Hohhot, Inner Mongolia, and maintains extensive manufacturing and distribution networks across China.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Inner Mongolia Yongye Biotechnology.